Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer Nancy Valente - Chief Development Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Dane Leone - RJS Etzer Darout - BMO Capital Markets Alec Stranahan - Bank of America Jerry Gong ...

Table of Contents FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ _______________________________________________ Commission file number: 001-36182 Xencor, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ ...

Xencor, Inc. (NASDAQ:XNCR) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Nancy Valente - Chief Development Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Securities Etzer Darout - BMO Capital Markets Edward Tenthoff - Piper Sandler Brian Chang - JPMorgan Alec Stranahan - Bank of America Merrill Lynch Kaveri Pohlman - BTIG C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ _______________________________________________ Commission file number: ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications, Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Nancy Valente - Chief Development Officer Conference Call Participants Supawat Thongthip - Mizuho Edward Tenthoff - Piper Sandler Brian Cheng - JPMorgan David Nierengarte ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (Address of principal executive offices) (Zip Code) (626) 305-5900 (Registrant's telephone number, including area code) Securities registered pursuant to Sec ...

Table of Contents` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _________________________ ...

Xencor, Inc. (NASDAQ:XNCR) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President and CEO Allen Yang - Chief Medical Officer John Kuch - CFO John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Edward Tenthoff - Piper Sandler Dane Leone - Raymond James Etzer Darout - BMO Capital Markets David Dai - SMBC Charles Zhu - Guggenheim Partners William Maughan - Can ...

Proteins by Design® XmAb® Antibody & Cytokine Therapeutics ® Corporate Overview November 2022 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the tim ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $27.3 million, with total revenue for the first nine months of 2022 at $143 million, primarily from royalty revenue related to partnerships with Vir and Alexion [16][18] - Total cash, cash equivalents, receivables, and marketable debt securities at September 30 totaled $564.6 million, down from $664.1 million at the beginning of the year, with an updated year-end cash position guidance of $575 million to $600 million [17][18] Business Line Data and Key Metrics Changes - XmAb564, a reduced potency cytokine targeting regulatory T-cells, showed promising biomarker data in a Phase 1 single-dose study, indicating well-tolerated subcutaneous administration and significant Treg expansion [10][23] - Vudalimab, a Phase 2 PD-1 by CTLA-4 dual checkpoint bispecific antibody, is enrolling patients for studies in metastatic castration-resistant prostate cancer and advanced gynecologic tumors [11][12] Market Data and Key Metrics Changes - The company is focusing on autoimmune diseases and oncology, leveraging its modular protein engineering tools to create a diverse development portfolio [9][10] - The Phase 1a study of XmAb564 demonstrated a significant increase in CD25 bright Treg counts, with a peak of about 150 cells per microliter at the highest dose [40] Company Strategy and Development Direction - The company aims to use proof-of-concept data from early-stage studies to guide the advancement, termination, or partnering of programs, focusing resources on those with the greatest potential for success [10] - XmAb564 is positioned as a potential best-in-class treatment in autoimmune diseases, with plans to explore multiweek dosing schedules in ongoing studies [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of XmAb564 and its ability to provide durable Treg expansion, which could lead to improved therapeutic profiles in autoimmune diseases [50][51] - The company is committed to advancing its pipeline quickly while monitoring biomarker data to inform dosing strategies [65][66] Other Important Information - The company has sufficient cash and equivalents to fund R&D programs and operations through the end of 2025 [18] - XmAb564 is the second clinical program in the XmAb cytokine platform, with plans for additional programs to follow [52][53] Q&A Session Summary Question: Duration of dosing for atopic dermatitis and psoriasis patients - Management indicated that patients will be dosed for eight weeks, primarily focusing on biomarker data [59][60] Question: Comparison of XmAb564 with other drugs in development - Management highlighted that XmAb564's half-life and Treg expansion metrics are competitive compared to other therapies, suggesting a strong position in the market [70] Question: Insights on anti-drug antibodies - No evidence of anti-drug antibodies was observed in the early analysis of XmAb564 [107] Question: Recruitment for plamotamab combination trials - Recruitment for plamotamab is ongoing, with studies expanding beyond the U.S. [68] Question: Variability in Treg expansion data - Management expressed confidence in the data despite variability due to small sample sizes, emphasizing consistent trends across multiple measures [119][120]